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When an enzyme is mentioned in theWhite House, even if only
in the world of the popular television dramaWestWing, it is clear
that this enzyme has earned a wide reputation. So the statement
of a female doctor attending the First Lady’s dinner party indicat-
ing that sphingosine kinase controls ‘‘all signal pathways to cancer
growth’’ suggests that this enzyme, and its product sphingosine-
1-phosphate (S1P), have gained prominence in the scienti¢c
community. Why have sphingosine kinase and S1P entered the
popular media? In other words, what is the evidence of their
importance?
Sphingosine kinase is a component of the sphingolipid meta-
bolic pathway (Fig 1). Sphingosine kinase phosphorylates sphin-
gosine, formed by deacylation of ceramide, to yield S1P. In turn,
ceramide is well known as a structural component of the skin,
where ceramides help to form the epidermal water^permeability
barrier. Indeed, the epidermis synthesizes some unique ceramides,
such as omega-hydroxyceramides (Behne et al, 2000) and phyto-
sphingosine-containing ceramides (Hamanaka et al, 2002). How-
ever, perhaps less well known to those in the dermatologic ¢eld is
the role of ceramide as a lipid second messenger. A little over a
decade ago, reports began to surface concerning the ability of cer-
tain cytokines and other signals to activate a sphingomyelinase
activity that hydrolyzes sphingomyelin to form ceramide and
phosphorylcholine (reviewed in Kolesnick, 2002). In addition,
using synthetic analogs to mimic the e¡ects of sphingomyeli-
nase-activating agents, these investigators demonstrated the abil-
ity of ceramide to function as a signaling molecule. A large
number of subsequent studies have shown that ceramide can also
be generated by a de novo pathway (Fig 1) and that ceramide func-
tions mostly as an antiproliferative second messenger. Thus, in-
creases in ceramide are often associated with growth arrest,
di¡erentiation, senescence and apoptosis, as has been shown in
numerous cell types (reviewed in Kolesnick, 2002 and Hannun
and Obeid, 2002), including keratinocytes (e.g., Bektas et al,
2000).
Consistent with the idea of ceramide as an antiproliferative sig-
nal, hyperproliferative cancer cells, which often evade the apop-
tosis usually triggered by ceramide-increasing agents, have been
found to utilize multiple metabolic enzymes to decrease ceramide
levels. For instance, multidrug-resistant cells express higher activ-
ities of the enzyme glucosylceramide synthase, which glycosylates
the ceramide formed in response to chemotherapeutic agents to
produce glucosylceramide and reduce ceramide levels (Fig 1 and
reviewed in Hannun and Obeid, 2002).This enzyme also protects
keratinocytes against ceramide-induced stress/apoptosis by con-
verting ceramide to glucosylceramide (Uchida et al, 2002). Trans-
formed cells have also been shown to exhibit increased activity of
the enzyme, sphingomyelin synthase (Luberto and Hannun,
1998), which transfers the choline headgroup from phosphatidyl-
choline to ceramide to generate sphingomyelin and diacylgly-
cerol (Fig 1). Other studies have indicated that provision of
sphingolipids in the diet reduces tumor formation in mice treated
with a carcinogen to induce the development of colon cancer and
genetically predisposed to develop colon cancer (Vesper et al, 1999
and Schmelz et al, 2001). Sphingolipids can inhibit the develop-
ment of skin carcinomas as well (Birt et al, 1998).
On the other hand, still other research has suggested that
agents that increase ceramide can also trigger proliferative re-
sponses. For instance, mitogenic growth factors can activate cera-
midase, which deacylates ceramide to form sphingosine
(reviewed in Spiegel et al, 1998). Sphingosine, in turn, can be
phosphorylated by sphingosine kinase to yield sphingosine
1-phosphate. This lipid metabolite acts as a ¢rst messenger by
binding to a family of GTP-binding protein-coupled receptors,
the S1P receptors (formerly known as the endothelial di¡erentia-
tion gene, or EDG, receptorsCsee Chun et al, 2002), although
other data also suggest possible intracellular sites of S1P action
(reviewed in Spiegel et al, 1998). In most cell systems (but see be-
low) S1P mediates proliferative cell responses and/or cell survival
(reviewed in Spiegel et al, 1998). Thus, the combined activities of
ceramidase and sphingosine kinase may account for the observa-
tion that some ceramide-elevating agents increase proliferation.
Indeed, in human keratinocytes 1,25-dihydroxyvitamin D3-sti-
mulated sphingomyelinase activation does not lead to apoptosis
because of the concominant generation of S1P (Manggau et al,
2001). In addition, the activity of sphingosine kinase can be regu-
lated by protein kinase C (reviewed in Spiegel et al, 1998), which
may explain the ¢nding that the ability of an agent to trigger
apoptosis may depend on the activation status of diacylglycerol-
activated protein kinase C. Thus, regulation of the interconver-
sion of di¡erent pro- and antiapoptotic sphingolipid metabolites,
as well as pathways of glycerolipid metabolism, may determine
the ultimate cellular response to various agents.
On the other hand, in this issue of the Journal of Investigative Der-
matology Vogler et al demonstrate that in keratinocytes (but not
dermal ¢broblasts) S1P functions as an antiproliferative, prodi¡er-
entiative signal. The mechanism underlying the opposite e¡ect of
S1P in keratinocytes versus dermal ¢broblasts (as well as other cell
types) is not known. This antiproliferative, prodi¡erentiative ef-
fect in keratinocytes also seems paradoxical based on their obser-
vation that S1P has the additional capacity to stimulate the
migration of these cells. It can be speculated, however, that S1P,
released from platelets at sites of wounding, may stimulate heal-
ing and reepithelialization by recruiting keratinocytes to the site
and inducing their di¡erentiation to mature cells. Moreover, the
mechanism by which S1P exerts its function is not entirely clear,
since Vogler et al provide evidence of G-protein-coupled S1P re-
ceptors both in keratinocytes in vitro and in the epidermis, as well
as possible intracellular actions of this lipid messenger.
A component(s) of the sphingolipid pathway may also play a
role in atopic dermatitis. Thus, Imokawa and colleagues have dis-
covered increased levels of a novel sphingolipid-metabolizing
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enzyme only in atopic dermatitis patients, but not in normal con-
trols or those with contact dermatitis or chronic eczema (Murata
et al, 1996). This enzyme, glucosylceramide sphingomyelin deacy-
lase, removes the acyl group from sphingomyelin (and gluco-
sylceramide) to produce sphingosylphosphorylcholine (and
glycosylated sphingosylphosphorylcholine) (Higuchi et al, 2000).
Indeed, sphingosylphosphorylcholine (SPC) is up-regulated in
the stratum corneum of atopic dermatitis patients (Okamoto
et al, 2003). SPC, in turn, is thought to function as a ligand for
G-protein-coupled SPC receptors, similar to the S1P receptors,
and trigger cellular responses such as enhanced transglutaminase
activity (Higuchi et al, 2001). In addition, SPC increases intercel-
lular cellular adhesion molecule-1 (ICAM-1) expression on kera-
tinocytes (Imokawa et al, 1999). Since ICAM-1 can recruit
leukocytes from the circulation, this e¡ect may contribute to the
presence of activated immune cells in patients with atopic derma-
titis. In addition, the loss of the sphingomyelin substrate from the
epidermis of these patients might also contribute to another fea-
ture of the diseaseCreduced epidermal ceramide levels (see refer-
ences cited in Murata et al, 1996), which may mediate, at least in
part, the observed symptom of skin dryness. Whether this de-
crease in ceramide also alters a signaling pathway, in addition to
its e¡ects on the lipid permeability barrier, is not yet clear.
On the other hand, it is clear that metabolites of the sphingo-
lipid pathway play an important role in epidermal physiology.
Obviously, some of these sphingolipids function as structural
components of the lipid permeability barrier. As shown in this
issue, another member of this pathway, S1P functions as a signal
to activate several G-protein-coupled S1P receptor subtypes, as
well as possibly acting intracellularly. Another metabolite, SPC
may also a¡ect keratinocyte cellular responses, possibly through
G-protein-coupled S1P-like receptors. Undoubtedly, an under-
standing of the interconversion of these lipid structural and sig-
naling molecules is essential, and additional studies, like the one
by Vogler et al on the role and actions of sphingolipids in kerati-
nocytes and in the epidermis are necessary.
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Figure1. Ceramide and Sphingolipid Metabolic Pathways.
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